Guardian Pharmacy Services (GRDN) Expected to Announce Earnings on Thursday

Guardian Pharmacy Services (NYSE:GRDN) is expected to be posting its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect the company to announce earnings of $0.3146 per share and revenue of $365.76 million for the quarter. Investors can find conference call details on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

Guardian Pharmacy Services (NYSE:GRDN) last announced its quarterly earnings results on Thursday, August 6th. The company reported $0.29 EPS for the quarter, beating the consensus estimate of $0.26 by $0.03. Guardian Pharmacy Services had a net margin of 4.50% and a return on equity of 29.97%. The company had revenue of $351.77 million for the quarter, compared to analyst estimates of $340.45 million. On average, analysts expect Guardian Pharmacy Services to post $1.18 EPS for the current fiscal year and $1.33 EPS for the next fiscal year.

Guardian Pharmacy Services Price Performance

Shares of NYSE:GRDN opened at $40.38 on Thursday. The company’s fifty day moving average price is $40.96 and its 200 day moving average price is $37.91. Guardian Pharmacy Services has a 12 month low of $26.34 and a 12 month high of $48.33. The firm has a market capitalization of $2.01 billion, a P/E ratio of 39.20, a P/E/G ratio of 2.06 and a beta of 0.03.

Analysts Set New Price Targets

Several analysts have commented on the company. Oppenheimer upped their price objective on Guardian Pharmacy Services from $43.00 to $49.00 and gave the company an “outperform” rating in a research note on Friday, August 7th. Weiss Ratings downgraded Guardian Pharmacy Services from a “buy (b)” rating to a “buy (b-)” rating in a research note on Friday, October 23rd. Wall Street Zen downgraded shares of Guardian Pharmacy Services from a “buy” rating to a “hold” rating in a research report on Sunday. KeyCorp began coverage on Guardian Pharmacy Services in a report on Tuesday, September 22nd. They issued an “overweight” rating and a $52.00 price target for the company. Finally, Truist Financial raised their price objective on shares of Guardian Pharmacy Services from $47.00 to $51.00 and gave the company a “buy” rating in a research note on Monday, September 21st. Nine investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $45.57.

Guardian Pharmacy Services Company Profile

Guardian Pharmacy Services, Inc is a provider of pharmacy services focused primarily on residents of long-term care and other institutional healthcare settings. Through its network of pharmacies, the company supplies prescription medications and related pharmacy support to assisted living communities, skilled nursing facilities, behavioral health organizations, and other care providers.

The company’s services include medication dispensing and packaging, prescription delivery, medication management, clinical pharmacy support, and technology-enabled tools designed to help caregivers and healthcare professionals manage residents’ medication regimens.